A repurposed drug used to treat arthritis did not significantly improve the outcomes of patients with severe COVID-19 pneumonia. Tocilizumab did not significantly improve clinical status or mortality rate at 28 days for participants who received it compared to a placebo.
Using induced pluripotent stem cells (iPSCs) and deleting a key gene, researchers at University of California San Diego School of Medicine have created natural killer cells — a type of immune cell — with measurably stronger activity against a form of leukemia, both in vivo and in vitro.
In a Phase III clinical trial, the drug volanesorsen significantly reduced blood fat (triglyceride) levels in participants with a rare disease called familial chylomicronemia syndrome; finding could also help inform better prevention methods and treatments for many types of heart disease.
UC San Diego School of Medicine researchers identified chemical compounds that prevent stress-induced clumping of TDP-43 protein in ALS motor neurons grown in the lab — a starting point for new ALS therapeutics.
Researchers at UC San Diego School of Medicine generated a new mouse model that mimics human acne for the first time, and used it to validate the concept of “good” and “bad” acne bacteria and introduce new possibilities for targeted treatments and vaccines.
UC San Diego Health is among 31 health facilities selected from across the state to participate in the California Bridge Program, an accelerated, 18-month training program for health care providers to enhance access to around-the-clock treatment for patients with opioid use disorder.
Researchers at University of California San Diego School of Medicine will expand a statewide program to prevent driving under the influence of alcohol, cannabis and prescription drugs.
Health Media Contacts
Find the best contact for health-related media inquiries.
